
Becton, Dickinson & Co. Experiences Valuation Adjustment Amidst Competitive Market Landscape
2025-11-10 15:28:28Becton, Dickinson & Co. has recently adjusted its valuation, with its current price at $177.84. Over the past year, the company has experienced a decline, contrasting with the S&P 500's performance. Key metrics include a P/E ratio of 33 and a dividend yield of 1.81%, indicating competitive positioning within the sector.
Read More
Becton, Dickinson & Co. Hits New 52-Week Low at $162.50
2025-11-07 15:54:50Becton, Dickinson & Co. has reached a new 52-week low, reflecting a notable decline over the past year. The company, with a market capitalization of USD 70.27 billion and a P/E ratio of 33.00, faces challenges in long-term growth despite a commitment to shareholder returns through dividends.
Read MoreIs Becton, Dickinson & Co. technically bullish or bearish?
2025-11-05 11:19:15As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and daily moving averages also indicate a bearish trend. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%, and a one-year return of -23.89% versus 19.89% for the index....
Read MoreIs Becton, Dickinson & Co. overvalued or undervalued?
2025-11-05 11:09:50As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from very expensive to expensive. This suggests that the company is currently overvalued. Key valuation ratios include a P/E ratio of 33, an EV to EBITDA of 16.57, and a PEG ratio of 2.36, all indicating a premium valuation relative to its peers. For comparison, Abbott Laboratories has a P/E of 18.36 and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, highlighting that Becton, Dickinson & Co. is trading at a higher valuation than these competitors. In terms of recent performance, Becton, Dickinson & Co. has underperformed significantly against the S&P 500, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%. This further reinforces the notion that the stock may be overvalued in the current market environment....
Read More
Becton, Dickinson & Co. Experiences Revision in Stock Evaluation Amid Market Challenges
2025-11-04 15:36:46Becton, Dickinson & Co. has recently faced a revision in its market evaluation, with its stock price reflecting notable volatility over the past year. Technical indicators suggest a bearish outlook, and the company's performance has lagged behind the S&P 500, indicating challenges in the current market environment.
Read MoreIs Becton, Dickinson & Co. technically bullish or bearish?
2025-11-04 11:30:41As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the overall bearish signals from Bollinger Bands and KST. The MACD shows a mildly bullish trend on the weekly chart but is bearish on the monthly chart, which adds to the mixed signals. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -21.85% compared to the S&P 500's 16.30%....
Read MoreIs Becton, Dickinson & Co. overvalued or undervalued?
2025-11-04 11:15:48As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 33, an EV to EBITDA of 16.57, and a Price to Book Value of 2.52, all of which suggest that the stock is priced higher than its fundamental value relative to peers. In comparison to its peers, Abbott Laboratories has a more attractive P/E ratio of 18.36, while Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, both indicating better value propositions. Becton, Dickinson & Co. has significantly underperformed against the S&P 500, with a year-to-date return of -21.85% compared to the index's 16.30%, reinforcing the notion that the stock is overvalued....
Read More
Becton, Dickinson & Co. Experiences Revision in Stock Evaluation Amid Market Challenges
2025-11-03 15:30:19Becton, Dickinson & Co. has recently adjusted its valuation, with its stock price at $178.71. Over the past year, the company has experienced a significant decline in stock return compared to the S&P 500. Key financial metrics indicate a higher P/E ratio than some competitors, highlighting industry challenges.
Read MoreIs Becton, Dickinson & Co. technically bullish or bearish?
2025-11-03 11:29:53As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators including a bearish signal from the daily moving averages and both weekly and monthly Bollinger Bands. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The KST is mildly bearish weekly and bearish monthly, while Dow Theory indicates a mildly bearish weekly and mildly bullish monthly trend. In terms of performance, Becton, Dickinson & Co. has underperformed the S&P 500 across multiple periods, with a year-to-date return of -21.23% compared to the S&P 500's 16.30%, and a one-year return of -23.49% versus 19.89% for the index....
Read More





